Keywords: good, pasi, scores, serono, raptiva, swiss, biotechnology
Good PASI scores for Serono's Raptiva
Article | 06 November 2006
Swiss biotechnology firm Serono has reported good data from the CLEAR study, which is the first multinational, randomized, double-blind, placebo-controlled, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
